
Opinion|Videos|January 10, 2025
Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas
Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.
Advertisement
Video content above is prompted by the following:
What considerations should guide the sequencing of bispecific therapies in first-line vs later-line settings?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
3
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
4
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
5